logo

For the Inventor, By the Inventor

Pennsburg, PA, United States of America

William C Lumma, Jr

This inventor holds 51 USPTO granted patents, primarily in Cardiovascular Agents (CPC class 5142). Top assignees: Merck + Co., Inc., Schering Aktiengesellschaft, Berlex Laboratories, Inc.. Active years: 1978-2007.

IDiyas Innovation Intelligence. (2026). Inventor Profile: William C Lumma, Jr. Retrieved from https://idiyas.com/inventor/william-c-lumma-jr

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 51

% Patents Active = 98.0

Average Co-Inventor Count = 3.0

ph-index = 12

Forward Citations = 512(Granted Patents)

Forward Citations (Not Self Cited) = 496(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • Lansdale, PA (US) (1978)
  • Pennsburg, PA (US) (1978 - 2002)
  • Helena, MO (US) (2007)

Company Filing History:

goldMedal37 out of 4,770 
 
Merck + Co., Inc.
 patents
silverMedal13 out of 1,409 
 
Schering Aktiengesellschaft
 patents
bronzeMedal1 out of 100 
 
Berlex Laboratories, Inc.
 patents

Years Active: 1978-2007

Loading Chart...
Areas of Expertise:
Tyrosine Kinase Inhibitors
Thrombin Inhibitors
HIV Reverse Transcriptase
Farnesyl-Protein Transferase
Cardiovascular Agents
Antiarrhythmic Imidazoles
Benzoxazinones
Pyridinone Inhibitors
Prodrugs
Gastric Secretion Inhibitors
Amino-Phenyl-Thiadiazoledioxides
Substituted Sulfonamidobenzamides
51 patents (USPTO):Explore Patents
1. 7265134 - Tyrosine kinase inhibitors (2007-09-04),
2. 6376496 - Inhibitors of prenyl-protein transferase (2002-04-23),
3. 6358956 - Inhibitors of prenyl-protein transferase (2002-03-19),
4. 6355643 - Inhibitors of prenyl-protein transferase (2002-03-12),
5. 6335343 - Inhibitors of prenyl-protein transferase (2002-01-01),
6. 6127390 - Inhibitors of prenyl-protein transferase (2000-10-03),
7. 5990107 - Fibrinogen receptor antagonist prodrugs (1999-11-23),
8. 5977134 - Inhibitors of farnesyl-protein transferase (1999-11-02),
9. 5939439 - Inhibitors of farnesyl-protein transferase (1999-08-17),
10. 5811423 - Benzoxazinones as inhibitors of HIV reverse transcriptase (1998-09-22),
11. 5798377 - Thrombin inhibitors (1998-08-25),
12. 5792779 - Pyridinone thrombin inhibitors (1998-08-11),
13. 5747490 - Alpha 1b adrenergic receptor antagonists (1998-05-05),
14. 5714485 - Piperidine and hexahydropyridazine thrombin inhibitors (1998-02-03),
15. 5665720 - Benzoxazinones as inhibitors of HIV reverse transcriptase (1997-09-09),

Title: The Innovative Journey of William C Lumma, Jr

Introduction:

William C Lumma, Jr, a talented inventor hailing from Pennsburg, PA, has made significant contributions to the world of innovation through his groundbreaking ideas and inventions.

Latest Patents:

William C Lumma, Jr holds several patents in various fields, showcasing his diverse range of expertise and creativity in inventing new solutions to existing problems.

Career Highlights:

Throughout his illustrious career, William C Lumma, Jr has demonstrated a keen eye for identifying gaps in the market and developing innovative products to fill those voids. His passion for creating practical solutions has led to the successful commercialization of several of his inventions.

Collaborations:

William C Lumma, Jr has collaborated with leading industry experts, researchers, and engineers to bring his ideas to life. These collaborations have not only enhanced the quality of his inventions but have also paved the way for future groundbreaking innovations.

Conclusion:

In conclusion, William C Lumma, Jr's relentless pursuit of innovation and his unwavering dedication to creating impactful solutions have solidified his position as a respected inventor in the industry. His contributions continue to inspire aspiring inventors and shape the future of technology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…